Board of Directors

Michael Altman, CFA
Michael Altman, CFA
Managing Director, Perceptive Advisors

Michael Altman joined Perceptive in 2007 and is a Managing Director on the investment team. His focus is on medical devices, diagnostics, digital health and specialty pharmaceuticals. He is also a member of the investment committee for the credit opportunities fund. Prior to Perceptive he was a healthcare trader and analyst at First New York Securities. Michael graduated from the University of Vermont with a B.S. in Business Administration. Michael serves on the board of directors for Vensun Pharmaceuticals and Vitruvius Therapeutics.

Edward Anderson
Edward Anderson
Founder, Northbridge Venture Partners

Ed Anderson is the founder of North Bridge Venture Partners and North Bridge Growth Equity. He raised nearly $4 billion in capital for those partnerships. For the past 35 years, Ed has provided financing and advised entrepreneurs focused on building game changing companies. He is a pioneer in the strategy of seed investing for high tech companies and has produced industry leading returns for investors. He serves on the boards of many private companies and has numerous philanthropic interests outside of North Bridge. Ed is a graduate of the University of Denver and the Columbia University Graduate School of Business

Robert Langer, D.Sc.
Robert Langer, D.Sc.
David H. Koch Institute Professor, Massachusetts Institute of Technology, Co-Founder

Robert Langer is one of 13 Institute Professors at MIT; being an Institute Professor is the highest honor that can be awarded to a faculty member. Dr. Langer has written more than 1,400 articles. He also has over 1,300 issued and pending patents worldwide. Dr. Langer’s patents have been licensed or sublicensed to over 350 pharmaceutical, chemical, biotechnology and medical device companies. He is the most cited engineer in history. He served as a member of the United States Food and Drug Administration’s SCIENCE Board, the FDA’s highest advisory board, from 1995 — 2002 and as its Chairman from 1999-2002. Dr. Langer has received over 220 major awards. He is one of four living individuals to have received both the United States National Medal of Science (2006) and the United States National Medal of Technology and Innovation (2011). He also received the 2002 Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers; the 2008 Millennium Prize, the world’s largest technology prize; the 2012 Priestley Medal, the highest award of the American Chemical Society; and the 2015 Queen Elizabeth Prize for Engineering. Among his multiple accolades, Forbes Magazine selected Dr. Langer as “one of the 25 most important individuals in biotechnology in the world” and “one of the 15 innovators worldwide who will reinvent our future.” He holds 33 honorary doctorates. He received his Bachelor’s Degree from Cornell University in 1970 and his Sc.D. from the Massachusetts Institute of Technology in 1974, both in Chemical Engineering.

Ann Merrifield
Ann Merrifield
Life Sciences Advisor and Board Director

Ann Merrifield has spent much of her career leading the development and growth of emerging biotechnology businesses. She currently serves as board director for a portfolio of public and private companies in the life sciences sector. Previously, she spent an 18-year career at Genzyme Corporation, a diversified global biotechnology company. While at Genzyme, Ann served as President, Genzyme Biosurgery, where she led global business strategy and operations across a portfolio of biologics and therapeutic devices. She also served as President, Genzyme Genetics, playing a key role in developing this start-up genetic diagnostics business and bringing it to profitability. Following Genzyme from 2012-2014, she served as CEO of PathoGenetix, developer of an automated system for rapid identification and typing of pathogenic bacterial strains. Earlier in her career, Ann was a Partner at Bain and Company, a global strategy consulting firm and an Investment Officer at Aetna Life & Casualty. Ann is a graduate of the University of Maine and the Amos Tuck School of Business at Dartmouth College.

Maria Palasis, Ph.D.
Maria Palasis, Ph.D.
President and Chief Executive Officer

Maria Palasis is an industry veteran in merging material science and drug-delivery innovation to create best-in-class therapies for patients. She brings nearly 25 years of healthcare industry experience to Lyra. A repeat entrepreneur, her transformative leadership as CEO, and previously CTO, of 480 Biomedical and Arsenal Medical resulted in >$160 million of external and non-dilutive funding and the advancement of multiple programs into the clinic. Earlier in her career, she managed a portfolio of external biotech and medical device investments at Boston Scientific and led the development of several combination therapies. She is an inventor on more than 120 issued and pending patents. Maria received her B.S. and Ph.D. in Chemical Engineering from the University of Cincinnati, and she held a postdoctoral fellowship in molecular biology at the University of Cincinnati School of Medicine.

George Whitesides, Ph.D.
George Whitesides, Ph.D.
Woodford L. and Ann A. Flowers University Professor, Harvard University, Co-Founder

Dr. Whitesides joined Harvard’s department of chemistry in 1982 and served as department chairman from 1986 to 1989. From 1963 to 1982, he was a faculty member at Massachusetts Institute of Technology. Dr. Whitesides held advisory positions on the National Research Council, National Science Foundation and the Department of Defense’s Defense Advanced Research Projects Agency (DARPA), and he is a member of the American Academy of Arts and Sciences, National Academy of Sciences, National Academy of Engineering and the American Philosophical Society, among other organizations. He has received dozens of honors, including the American Chemical Society (ACS) Award in Pure Chemistry (1975), the Arthur C. Cope Award (1995), the DARPA Award for Significant Technical Achievement (1996), the National Medal of Science (1998), the Von Hippel Award (2000), the Kyoto Prize (2003), the Dan David Award (2005), the Welch Award (2005), the Priestley Award (2007), the American Institute of Chemists Gold Medal (2007), the Prince of Asturias Foundation Award (2008), the Nanoscience Prize (2008), the Wheland Medal (2008) and the Benjamin Franklin Medal in Chemistry (2009). George is a co-founder of a number of companies including Genzyme, GelTex, Theravance and Arsenal Medical. He received a Bachelor of Arts from Harvard University in 1960 and a doctorate from the California Institute of Technology in 1964.

Back to Top